Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-AM: Neoadjuvant Pucotenlimab, Lenvatinib, and Temozolomide in Acral Melanoma
NCT07501104Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2026
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of pucotenlimab in acral lentiginous melanoma (ALM), sponsored by Zhongshan Hospital, Fudan University. Planned start May 2026; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT07501104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501104.